NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 325
(Total Views: 164)
Posted On: 05/08/2023 4:38:47 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Bettina M. Cockroft, M.D., M.B.A., to its board of directors. Dr. Cockroft, a well-established industry executive with over 30 years of experience in the biopharmaceutical industry with clinical development expertise across multiple therapeutic areas, will serve as an independent director. “On behalf of the CNS Pharmaceuticals board and management, we are thrilled to welcome Dr. Cockroft to the board. Her appointment adds deep scientific, clinical and operational expertise, and we believe that she will provide an integral viewpoint and invaluable guidance,” said Faith L. Charles, CNSP board chair. “Dr. Cockroft’s addition to our team is another representation of our commitment to advancing Berubicin and the company’s planning for success in order to serve patients in desperate need of a treatment, as well as building value for shareholders in the near and long term. Additionally, her European training provides an important perspective on our expanding clinical operations in that important region. We look forward to leveraging her proven leadership and extensive expertise moving forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Bettina M. Cockroft, M.D., M.B.A., to its board of directors. Dr. Cockroft, a well-established industry executive with over 30 years of experience in the biopharmaceutical industry with clinical development expertise across multiple therapeutic areas, will serve as an independent director. “On behalf of the CNS Pharmaceuticals board and management, we are thrilled to welcome Dr. Cockroft to the board. Her appointment adds deep scientific, clinical and operational expertise, and we believe that she will provide an integral viewpoint and invaluable guidance,” said Faith L. Charles, CNSP board chair. “Dr. Cockroft’s addition to our team is another representation of our commitment to advancing Berubicin and the company’s planning for success in order to serve patients in desperate need of a treatment, as well as building value for shareholders in the near and long term. Additionally, her European training provides an important perspective on our expanding clinical operations in that important region. We look forward to leveraging her proven leadership and extensive expertise moving forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CNS Pharmaceuticals Inc. (CNSP) Stock Research Links
Scroll down for more posts ▼